Vanguard Group’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
– Sell
-1,378,939
Closed -$752K – 4152
2016
Q3
$752K Sell
1,378,939
-227,956
-14% -$104K ﹤0.01% 3651
2016
Q2
$934K Sell
1,606,895
-446,494
-22% -$477K ﹤0.01% 3624
2016
Q1
$3M Buy
2,053,389
+235,776
+13% +$465K ﹤0.01% 3209
2015
Q4
$5.82M Buy
1,817,613
+151,206
+9% +$727K ﹤0.01% 2920
2015
Q3
$10.4M Buy
1,666,407
+66,603
+4% +$623K ﹤0.01% 2589
2015
Q2
$15.9M Buy
1,599,804
+326,197
+26% +$2.86M ﹤0.01% 2453
2015
Q1
$9.39M Buy
1,273,607
+54,287
+4% +$365K ﹤0.01% 2679
2014
Q4
$6.52M Buy
1,219,320
+96,886
+9% +$496K ﹤0.01% 2752
2014
Q3
$5.64M Buy
1,122,434
+146,575
+15% +$901K ﹤0.01% 2761
2014
Q2
$6.55M Buy
975,859
+128,231
+15% +$816K ﹤0.01% 2712
2014
Q1
$6.14M Buy
847,628
+134,370
+19% +$796K ﹤0.01% 2728
2013
Q4
$2.69M Buy
713,258
+340,567
+91% +$1.32M ﹤0.01% 3073
2013
Q3
$1.25M Buy
372,691
+2,120
+0.6% +$7.38K ﹤0.01% 3306
2013
Q2
$1.24M Buy
+370,571
New +$1.34M ﹤0.01% 3241

Other funds holding NWBO

Vanguard Group's NWBO Position: Q4 2016 in Review

Vanguard Group sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 1,378,939 shares — an estimated $752K sold.

Vanguard Group first reported a position in NWBO in Q2 2013 and held it in 14 quarters. The position peaked at $15.9M in Q2 2015. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

  • Vanguard Group reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
  • Vanguard Group sold 1,378,939 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $752K.
  • Vanguard Group first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2013 and held it in 14 quarters.
  • Vanguard Group's Northwest Biotherapeutics, Inc. Common stock position peaked at $15.9M in Q2 2015.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on Vanguard Group's 13F filing for Q4 2016, filed 14 Feb 2017.